We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Neurostimulation System Highly Effective in Cluster Headache

By HospiMedica International staff writers
Posted on 20 Feb 2013
A new device that is based on stimulation of the sphenopalatine ganglion (SPG) helps reduce the frequency of cluster headache attacks.

The ATI Neurostimulation System is a novel, rechargeable system, with an implantable miniaturized neurostimulator (smaller than an almond) that is placed via the mouth, leaving no externally visible scars. More...
Designed for the treatment of severe headache, the neurostimulator is activated using an external remote controller that is held up to the cheek, allowing the patient to deliver as-needed stimulation to relieve the attack. After a headache is treated, the remote controller is simply moved away, turning off the stimulation therapy. The ATI Neurostimulation System is a product of Autonomic Technologies (ATI; Redwood City, CA, USA), and has received the European Community (CE) marking of approval.

In a placebo-controlled clinical study, the ATI Neurostimulation System demonstrated effectiveness in treating cluster headache, and provided significant improvement in patient quality of life and headache disability. Pain relief at 15 minutes was achieved in 67.1% of treated attacks, compared to 7.4% of sham treated attacks. Pain freedom at 15 minutes was achieved in 34.1% of treated attacks, compared to 1.5% of sham treated attacks. The average number of cluster attacks per week was reduced by 31%, and 43% of patients experienced an average reduction of 88% in the number of attacks suffered. The study results were published early online on February 6, 2013, in Cephalalgia.

“Cluster headaches cause so much disability that patients are often unable to function normally,” said lead author Prof. Jean Schoenen, MD, PhD, coordinator of the headache research unit at the University of Liege (Belgium). “Current preventive treatments are often ineffective, and in many patients acute and preventive treatments may not be tolerated or are contraindicated. This new and innovative therapy offers a way for a significant number of patients to control the debilitating pain of cluster headache.”

Cluster headache is a highly disabling chronic neurological condition characterized by intense stabbing pain in the area of one eye, often accompanied by swelling, tears, and nasal congestion. Patients suffering from cluster headache may experience multiple attacks daily or almost daily, with each attack lasting between 15 minutes and three hours. Often called “suicide headaches” because of their severity, it is estimated that over 600,000 people across Europe alone suffer from cluster headaches.

Related Links:

Autonomic Technologies
University of Liege



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.